Congress trades
Crinetics Pharmaceuticals, Inc. (CRNX)
Free on iOS and Android.
About Crinetics Pharmaceuticals, Inc.
from the company's filings and listing, as of Oct 25, 2026- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- R. Scott Strutherslast on record
- Employees
- 594
- Listed since
- Jul 18, 2018
- Market value
- $9.0Blast quoted Sep 1, 2026
- Price to earnings (12 mo)
- -
- Net income per share, as reported (12 mo)
- -
- Dividend yield
- -
Earnings
6 reported quarters · next on Nov 5, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Aug 3, 2026 | -$1.14 | -$1.18 | $25.1M | $14.8M | EPS beatRevenue beat |
| Q1 FY2026reported May 7, 2026 | -$1.23 | -$1.22 | $10.7M | $8.5M | EPS in lineRevenue beat |
| Q4 FY2025reported Feb 26, 2026 | -$1.29 | -$1.37 | $6.2M | $4.5M | EPS beatRevenue beat |
| Q3 FY2025reported Nov 6, 2025 | -$1.38 | -$1.27 | $143K | $4.3M | EPS missRevenue miss |
| Q2 FY2025reported Aug 7, 2025 | -$1.23 | -$1.13 | $1.0M | $394K | EPS missRevenue beat |
| Q1 FY2025reported May 8, 2025 | -$1.04 | -$0.99 | $361K | $348K | EPS missRevenue beat |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for fiscal 2025 · proxy filed Apr 29, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| R. Scott Struthers, Ph.D.President and Chief Executive Officer | $719K | $3.3M | $7.6M | $11.6M |
| Tobin SchilkeChief Financial Officer | $452K | $1.8M | $2.2M | $4.4M |
| Dana Pizzuti, M.D.Chief Medical and Development Officer | $573K | $1.6M | $1.8M | $3.9M |
| Stephen F. Betz, Ph.D.Chief Scientific Officer | $520K | $1.6M | $1.7M | $3.8M |
| Jeff KnightChief Operating Officer | $512K | $1.6M | $1.7M | $3.8M |
The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. 1 executive who has since left the company is named in that filing and not shown here. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Shares vs prior qtr | % of shares out |
|---|---|---|---|---|
| FMR LLC | $592.7M | 15,840,219 | +0.5% | 15.01% |
| BlackRock, Inc. | $365.2M | 9,758,938 | +15.1% | 9.24% |
| Farallon Capital Management, L.L.C. | $336.4M | 8,989,098 | +7.8% | 8.52% |
| Wellington Management Group LLP | $266.8M | 7,131,084 | -12.6% | 6.76% |
| Driehaus Capital Management LLC | $241.9M | 6,463,551 | +1.1% | 6.12% |
| T. Rowe Price Associates, Inc. | $232.5M | 6,212,681 | +16.0% | 5.89% |
| Vanguard Portfolio Management LLC | $180.8M | 4,832,614 | +4.2% | 4.58% |
| Vanguard Capital Management LLC | $177.6M | 4,745,262 | +1.5% | 4.50% |
| Jupiter Topco LLC | $170.5M | 4,557,689 | New | 4.32% |
| Geode Capital Management, LLC | $102.1M | 2,727,633 | +10.0% | 2.58% |
| State Street Corp | $100.6M | 2,689,350 | +11.9% | 2.55% |
| Bellevue Group AG | $98.0M | 2,620,000 | -20.1% | 2.48% |
A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. New: not in this holder's prior 13F as reported; a change of filer ID can also show as new. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.
Tracked fund managers holding CRNX
4 managers| Manager | Value | Shares | Share of book |
|---|---|---|---|
| Farallon Capital | $336.4M | 8,989,098 | 1.6% |
| Baker Bros. AdvisorsJulian & Felix Baker | $88.0M | 2,351,465 | 0.4% |
| Montanova Capitalformerly Suvretta | $44.4M | 1,186,279 | 0.8% |
| OrbiMed | $37.4M | 999,000 | 0.7% |
4 of the 97 fund managers we track list CRNX shares among the largest positions in their latest 13F, filed for Q2 2026. A manager can hold it further down the book too, so this is a floor, not a count. Share of book is the position against the manager's whole disclosed 13F value.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Congress trades in CRNX
6 disclosures of 6 on record · median 21d of the 45 allowedSince the trade: the stock's move from the trade date to the last close under this ticker (Sep 1, 2026), not the member's result. Not investment advice.
| Member | Type | Action | Amount disclosed | Stock since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Gilbert Ray Cisneros, Jr. | Stock | Sale | $15,001 - $50,000 | +1.6%After the saleS&P 500 +3.4% · -1.8 pts vs S&P 500 | Jul 30, 2026 | Sep 4, 2026 | 36d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +111.7%S&P 500 +12.7% · +99.1 pts vs S&P 500 | Mar 3, 2026 | Apr 7, 2026 | 35d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +179.3%S&P 500 +45.7% · +133.6 pts vs S&P 500 | Apr 17, 2025 | May 6, 2025 | 19d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | +145.0%After the saleS&P 500 +35.2% · +109.8 pts vs S&P 500 | Mar 19, 2025 | Apr 10, 2025 | 22d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +115.7%S&P 500 +27.4% · +88.4 pts vs S&P 500 | Jan 29, 2025 | Feb 11, 2025 | 13d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | +68.4%S&P 500 +34.1% · +34.3 pts vs S&P 500 | Sep 25, 2024 | Oct 3, 2024 | 8d |
Since the trade is an estimate, set beside the S&P 500 over the same window, with the gap between the two in percentage points. The filing carries a band, not a fill, and a sale keeps the stock's sign, so a positive figure after a sale means the stock kept rising after it. An option row carries the underlying stock's move. A row marked n/a is one we hold no figure for.
A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.
"Not captured" means the band or the transaction type on the original report is missing from our data.
"Dates conflict" marks a row whose disclosure is dated before its trade on the record we hold. Both dates are printed as filed, and no since-the-trade figure is computed from them.
Every Congress trade in CRNX, filterable by party, chamber, type and account.
Questions
Which members of Congress have traded CRNX?
Gilbert Ray Cisneros, Jr. and Josh Gottheimer disclosed CRNX transactions in the filings shown here.
How quickly are CRNX trades disclosed?
Congressional disclosures took a median of 21 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Oct 26, 2026.